Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 134 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.  The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 4, 11 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology which include indications Rheumatoid Arthritis, Ulcerative Colitis, Atopic Dermatitis, Alopecia, Psoriasis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Auto Inflammatory Disease, Autoimmune Disorders, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Endometrial Cancer, Eosinophilia, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Giant Cell Arteritis, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Respiratory Tract Inflammatory Disorders, Sicca Syndrome (Sjogren), Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). 

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview 9
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 17
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment 25
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 29
AbbVie Inc 29
Aclaris Therapeutics Inc 29
Advinus Therapeutics Ltd 30
Astellas Pharma Inc 31
AstraZeneca Plc 31
Chipscreen Biosciences Ltd 32
CJ HealthCare Corp 32
Eli Lilly and Company 33
Galapagos NV 34
Incyte Corp 34
Japan Tobacco Inc 37
Jiangsu Hengrui Medicine Co Ltd 37
Nissan Chemical Industries Ltd 38
Pfizer Inc 38
Portola Pharmaceuticals Inc 39
Sareum Holdings Plc 40
Theravance Biopharma Inc 41
Vectura Group Plc 41
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles 42
ABBV-599 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ATI-50001 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ATI-50002 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
AZD-0449 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
AZD-1480 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AZD-4205 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
baricitinib - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
cerdulatinib - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CS-944X - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
filgotinib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
INCB-52793 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
itacitinib adipate - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
JTE-052 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
NIP-565 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
peficitinib hydrobromide - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
PF-04965842 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
PF-06700841 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
PNQ-401 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
PNQ-701 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
ruxolitinib phosphate - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
SAR-20347 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
SART-29 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
SHR-0302 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
TD-1473 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
TD-3504 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
upadacitinib tartrate - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
VR-588 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products 120
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products 121
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones 123
Featured News & Press Releases 123
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 123
May 15, 2017: Seven abstracts on filgotinib accepted by EULAR 2017 123
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 124
May 09, 2017: AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease 124
May 07, 2017: Galapagos presents three posters on filgotinib in Crohn's disease at DDW 2017 125
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 126
Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 127
Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib 127
Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 128
Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders 128
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 129
Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease 129
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 130
Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 131
Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis 132
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 133
Disclaimer 134

List of Tables

Number of Products under Development by Stage of Development, H1 2017 10
Number of Products under Development by Therapy Areas, H1 2017 11
Number of Products under Development by Indications, H1 2017 12
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 14
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 15
Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017 16
Number of Products under Development by Companies, H1 2017 17
Products under Development by Companies, H1 2017 18
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 19
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 20
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 21
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 22
Products under Development by Companies, H1 2017 (Contd..5), H1 2017 23
Products under Development by Companies, H1 2017 (Contd..6), H1 2017 24
Number of Products by Stage and Mechanism of Actions, H1 2017 25
Number of Products by Stage and Route of Administration, H1 2017 27
Number of Products by Stage and Molecule Type, H1 2017 28
Pipeline by AbbVie Inc, H1 2017 29
Pipeline by Aclaris Therapeutics Inc, H1 2017 30
Pipeline by Advinus Therapeutics Ltd, H1 2017 30
Pipeline by Astellas Pharma Inc, H1 2017 31
Pipeline by AstraZeneca Plc, H1 2017 31
Pipeline by Chipscreen Biosciences Ltd, H1 2017 32
Pipeline by CJ HealthCare Corp, H1 2017 32
Pipeline by Eli Lilly and Company, H1 2017 33
Pipeline by Galapagos NV, H1 2017 34
Pipeline by Incyte Corp, H1 2017 35
Pipeline by Japan Tobacco Inc, H1 2017 37
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 37
Pipeline by Nissan Chemical Industries Ltd, H1 2017 38
Pipeline by Pfizer Inc, H1 2017 38
Pipeline by Portola Pharmaceuticals Inc, H1 2017 39
Pipeline by Sareum Holdings Plc, H1 2017 40
Pipeline by Theravance Biopharma Inc, H1 2017 41
Pipeline by Vectura Group Plc, H1 2017 41
Dormant Projects, H1 2017 120
Discontinued Products, H1 2017 121
Discontinued Products, H1 2017 (Contd..1), H1 2017 122